Osteoporosis | Disease Landscape & Forecast | G7 | 2022

With an increasing prevalence owing to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers, increasing uptake of Evenity, and drug launches will support the market through 2031. However, market growth will be tempered by the generic erosion of key brands. The relatively low diagnosis and drug-treatment rates for osteoporosis, owing to the asymptomatic nature of the disease, will also continue to hold back the market. Driven largely by their widespread generic availability and strong physician familiarity, bisphosphonates continue to dominate first-line treatment, creating a significant barrier to uptake for novel therapies. Emerging therapies will need to demonstrate a significant risk-clinical benefit balance, at a competitive price, to challenge the bisphosphonates as first-line treatments. Therefore, most emerging therapies will compete for use as second- or third-line treatments.

Questions Answered:

  • What are the drivers and constraints in the osteoporosis market, and how will the market evolve over the forecast period?
  • How has Amgen / UCB’s Evenity been integrated into the U.S., U.K., and German treatment algorithm, and how will it be positioned in Japan and rest of the European market?
  • What do thought leaders think of the emerging therapies and the current treatment options and practices? How will uptake of the emerging agents impact current market-leading therapies?
  • What impact will the generic entries of key brands, such as Prolia, have on the osteoporosis market?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts.

Epidemiology: Prevalence of osteoporosis by country, with diagnosed and drug-treated population.


Emerging therapies: Phase III: 1 drug; Phase II: 1 drug. Coverage of select Phase I products.

Key drugs: Denosumab, teriparatide, abaloparatide SC, abaloparatide TD, EB-613, alendronate, romosozumab, raloxifene.

Market forecast features: 10-year, annualized, drug-level sales and patient share of key osteoporosis therapies through 2031, segmented by brands / generics.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report